Tavares, G., Marques, D., Barra, C., Rosendo-Silva, D., Costa, A., Rodrigues, T., . . . Matafome, P. (2021). Dopamine D2 receptor agonist, bromocriptine, remodels adipose tissue dopaminergic signalling and upregulates catabolic pathways, improving metabolic profile in type 2 diabetes.
Chicago Style (17th ed.) CitationTavares, G., et al. Dopamine D2 Receptor Agonist, Bromocriptine, Remodels Adipose Tissue Dopaminergic Signalling and Upregulates Catabolic Pathways, Improving Metabolic Profile in Type 2 Diabetes. 2021.
MLA (8th ed.) CitationTavares, G., et al. Dopamine D2 Receptor Agonist, Bromocriptine, Remodels Adipose Tissue Dopaminergic Signalling and Upregulates Catabolic Pathways, Improving Metabolic Profile in Type 2 Diabetes. 2021.
Warning: These citations may not always be 100% accurate.